A MP-activated protein kinase (AMPK) is known as a fuel gauge and a master regulator of cell metabolism. 1, 2 Activation of AMPK during cellular stress promotes ATP generation via increases of glucose uptake and fatty acid oxidation, whereas it inhibits energy consuming processes such as protein and lipid synthesis. These unique functions of AMPK make it an attractive drug target for metabolic and cardiovascular diseases, as well as cancer. AMPK is a heterotrimeric complex composed of a catalytic α-subunit and regulatory βand γ-subunits with multiple isoforms for each subunit. The γ-subunit is the energy sensor of the complex; competitive binding of ATP against ADP or AMP to the γ-subunit regulates the kinase activity. 3, 4 Two isoforms of the γ-subunit are expressed in the heart, γ1 and γ2. Point mutations in the nucleotide-binding region of the γ2-subunit, encoded by the Prkag2 gene, cause a distinct form of human cardiomyopathy characterized by glycogen storage, preexcitation arrhythmia, and cardiac hypertrophy. 5-7 Previous studies using mouse models expressing mutant Prkag2 genes in the heart recapitulated the characteristics of human cardiomyopathy and demonstrated that the phenotype was caused by an aberrant increase of kinase activity. 6, 8, 9 Metabolic analysis of the mutant mouse hearts shows that activation of AMPK in the absence of energy deficit results in global remodeling of the
metabolic network in favor of glycogen storage. 8, 10, 11 Because the cardiac phenotype of Prkag2 mutation is similar to glycogen storage cardiomyopathy, we sought to determine whether excessive glycogen accumulation is the unifying mechanism responsible for the Prkag2 cardiomyopathy. In a mouse model with cardiac-specific overexpression of the N488I mutant of Prkag2 (R2M), we rescued the glycogen storage phenotype by targeting glucose-6-phosphate (G6P)-stimulated glycogen synthesis via genetic manipulations. Here, we show that excessive glycogen accumulation is primarily responsible for ventricular preexcitation but not cardiac hypertrophy. Rather, the mutation of γ2-AMPK stimulates proliferation and hypertrophy pathways via forkhead box O transcription factor (FoxO) and mammalian target of rapamycin (mTOR) signaling cascades, leading to abnormal cardiac growth.
Methods

Animal Models
Transgenic mice overexpressing N488I AMPK γ2 (R2M), FoxO1 (FO), and harboring a knockin (KI) mutation in glycogen synthase (GYS) 1 were generated as described. 6, 12, 13 R2M-KI (DM) and R2M-FO (DM-FO) double mutant were generated on an FVB background. Wild-type littermates of transgenic mice were used as controls (NTG).
Two-week-old mice were treated with rapamycin (2 mg/kg body weight, IP) daily for 4 weeks. Rapamycin (LC Laboratories) was dissolved in DMSO and resuspended in vehicle (0.2% carboxymethyl cellulose and 0.25% polysorbate-80) before injection. For insulin injection, mice were fasted overnight and anaesthetized with pentobartital (80 mg/kg body weight, IP). Heart samples were freezeclamped 20 minutes after insulin (0.5 U/kg body weight, IP). For 5-bromo-2-deoxyuridine (BrdU)-labeling experiments, 1-week-old mice were injected with BrdU (50 mg/kg body weight, IP) daily for 7 days, and hearts were subsequently harvested and fixed in 10% neutral buffered formalin for immunohistochemistry. All animal procedures were approved by the Institutional Animal Care and Use committee at the University of Washington.
Echocardiography and ECG
Murine echocardiography was performed using a Vevo770 high resolution imaging system (VisualSonics Inc). ECG was recorded using implantable wireless monitoring device with DSI mouse ECG transmitter ETA-F10.
Cardiac GYS Activity and Glycogen Content
GYS activity was measured using the method of Thomas et al. 14 Glycogen content was determined by a glucose assay kit (Sigma-Aldrich) as described. 10 Glucose Uptake and Myocardial Energetics 31 P nuclear magnetic resonance spectroscopy was used to measure glucose uptake rate, ATP, and phosphocreatine with nontracer 2-deoxyglucose as described. 8, 10 Western Blot Analysis Protein samples were prepared from frozen heart samples using a lysis buffer containing protease inhibitors (Sigma). Nuclear and cytosolic fractions were prepared according to instructions of NE-PER extraction kit (Pierce). Tissue lysates were matched for protein concentration and then separated by SDS-PAGE and transferred onto a polyvinylidene difluoride membrane (Bio-Rad Laboratories). Membranes were blocked in 5% nonfat milk and incubated with primary antibodies overnight at 4°C. Membranes were incubated with appropriate secondary antibodies conjugated to horseradish peroxidase (Pierce), and signal intensities were visualized by Chemiluminescence (Cell Signaling Technology). Films from ≥4 independent experiments were scanned, and densities of the immunoreactive bands were evaluated using National Institutes of Health Image J software.
Immunohistochemistry
Mouse hearts were arrested in diastole with Krebs-Henseleit buffer containing 30 mmol/L KCl and fixed in 10% neutral buffered formalin. 6 After stained with appropriate antibodies, the positive signal was detected using confocal microscopy (Zeiss LSM510Meta).
Real-Time Polymerase Chain Reaction
Real-time polymerase chain reaction was performed using SYBR green (Bio-Rad) as described. 15 
Statistics
Data are expressed as a mean±SD. Comparisons among the groups were performed by 1-way ANOVA and followed by a post hoc Tukey-Kramer test. The comparison between 2 groups was performed using 2-tailed Student t tests. A P<0.05 was considered statistically significant.
Results
Rescue of Pathological Glycogen Storage in the R2M Heart Eliminated Ventricular Preexcitation But Did Not Affect Cardiac Hypertrophy
AMPK is an important regulator of glucose metabolism, and R2M hearts demonstrate significant increases in glucose uptake and intracellular [G6P], the major allosteric stimulator for glycogen synthesis. 10 To determine whether glycogen storage caused by excessive G6P accounts for the fundamental disease mechanisms of Prkag2 cardiomyopathy, we sought to block G6P stimulated glycogen synthesis in R2M hearts by introducing a KI mutation (R582A) in the muscle form of GYS1. The GYS activity was significantly reduced, and the response to G6P was eliminated in the heart of KI or DM mice ( Figure 1A ). Glycogen content was lower in KI heart, and glycogen accumulation was markedly reduced (by ≈6-fold; P<0.0001) in DM heart ( Figure 1B ). Reduced glycogen storage was also demonstrated by haematoxylin and eosin staining of heart sections in which intracellular vacuoles representing glycogen storage sites in live cells were prominent in R2M hearts but were absent in DM hearts ( Figure 1C ). The KI did not affect the expression of mutant γ2-AMPK, the AMPK activity, basal glucose uptake rate, or the myocardial energetic status of the R2M hearts (Online Figure I) .
Using ambulatory ECG recording, we found that the shortened PR interval present in the ECG of R2M mice, characteristic of ventricular preexcitation, 8 was restored in DM mice ( Figure 1D ). The abnormal annulus fibrosis structure was subsequently improved (Online Figure II) , which is in agreement with the previous findings that glycogen causes ventricular preexcitation by disruption of annulus fibrosis in R2M mice.
Nonstandard Abbreviations and Acronyms AMPK
AMP-activated protein kinase However, in spite of decreased glycogen content, heart weight (HW) to body weight ratios of DM (9.3±1.24 mg/g) remained similar to that of R2M (10.3±1.44 mg/g), and both were significantly greater than that of nontransgenic littermates (NTG, 4.3±0.17 mg/g) at 2 months ( Figure 1E ). In addition, crosssectional area of cardiac myocytes was ≈2-fold higher in either R2M or DM hearts compared with that in NTG hearts (P<0.01), suggesting marked cellular hypertrophy ( Figure 1F ). Abnormal cardiac growth in DM mice was further evidenced by increased left ventricular wall thickness assessed by echocardiography (Online Figure III) . Noticeably, the reduction of glycogen storage partially improved cardiac function of R2M mice (fractional shortening, 42±11% in DM versus 32±7% in R2M and 58±9% in NTG; P<0.01). These data indicate that the excessive glycogen accumulation is primarily responsible for ventricular preexcitation and partially accounts for the contractile dysfunction in the heart of R2M mice, whereas the cardiac hypertrophy phenotype is independent of glycogen storage.
Insulin Sensitivity Was Increased in R2M Hearts
It has been shown that AMPK inhibits mTOR signaling via phosphorylation of tuberin/TSC (Ser1387) and raptor (Ser792). 16, 17 Consistent with increased AMPK activity in R2M, we observed increased phosphorylation of TSC and raptor at these sites (Online Figure IV) . However, we also found that the phosphorylation level of Akt (S473) was significantly increased in R2M hearts ( Figure 2A ). Furthermore, a greater phosphorylation of TSC (Ser939, Thr1462) and raptor (Ser863) at the insulin-stimulated phosphorylation sites was observed ( Figure 2A ). The increased insulin-signaling pathway was also observed in DM hearts (Online Figure V) . To determine whether insulin signaling is enhanced in R2M hearts, we subjected R2M mice to overnight fasting and compared Akt activation to that in fed mice. Fasting completely inhibited the phosphorylation of Akt and its downstream targets, mTOR and ribosomal protein S6, compared with ad lib feeding in both control and R2M mutant hearts ( Figure 2B ). To determine whether the greater phosphorylation of Akt in fed R2M heart was because of increased sensitivity to insulin, we injected a low dose of insulin (0.5 U/kg, IP) in fasted mice. R2M hearts responded to insulin injection with a greater increase in the phosphorylation level of Akt (S473; Figure 2C ). It is unlikely that this is due to hyperinsulinemia because the cardiac-specific R2M mice did not develop systemic insulin resistance and showed no differences in body weight, blood glucose level, and glucose tolerance test (Online Figure VI) . Rather, this may result from suppressed serine phosphorylation of insulin receptor substrate 1 ( Figure 3A ) and a relief of negative feedback of p70S6 kinase on insulin-signaling pathway consistent with a previous finding that AMPK increased insulin-stimulated glucose transport via suppression of serine phosphorylation of insulin receptor substrate 1 in muscle cells. 18 In HEK293T cells expressing N488I mutant of γ2-AMPK, phosphorylation of Akt (S473) was also accentuated in response to low concentrations of insulin (0.1 and 1 nmol/L) compared with cells expressing green fluorescent protein ( Figure 2D ). Akt phosphorylation level did not differ between the 2 groups at high concentration of insulin (10 nmol/L). Taken together, these data indicate that mutation of γ2-AMPK increases insulin sensitivity both in vitro and in vivo, resulting in enhanced growth signaling mechanisms.
Activation of the mTOR Pathway Partially Contributes to Cardiac Hypertrophy in R2M
Consistent with increased insulin signaling, the phosphorylation level of mTOR was significantly increased in R2M hearts ( Figures  2B and 3A) . Increased mTOR activity was further evidenced by increased phosphorylation of its downstream targets, p70S6 kinase (by 3.5-fold), ribosomal protein S6 (by 3.7-fold), and eukaryotic translation initiation factor 4E-binding protein 1 (by 3.2-fold). We next sought to rescue the abnormal cardiac growth phenotype in R2M mice by decreasing mTOR activity through treatment with rapamycin. Two-week-old mice were treated with either vehicle or rapamycin (2 mg/kg IP) daily for 4 weeks. This time point was chosen because activation of Akt and mTOR was first detected in R2M mice at 2 weeks of age ( Figure 3B ). Rapamycin treatment effectively inhibited mTOR activity, manifested as the loss of S6 phosphorylation ( Figure 3C ). Rapamycin treatment as expected did not affect phosphorylation of Akt (S473) in either genotype. After 4-week treatment, heart size of rapamycin-treated R2M was reduced by 45% compared with that of vehicle-treated R2M, as measured by HW to tibia length ratios. The reduced HW was attributed to a decrease in the cardiomyocyte size because the crosssectional area of myocytes in rapamycin-treated R2M hearts was significantly decreased (Online Figure VII) . Rapamycin-treated control mice also showed a 20% reduction of HW tibia length ratios compared with vehicle-treated control. As a result, HW tibia length ratios of R2M-rapamycin remained ≈87% greater than that of NTG-rapamycin ( Figure 3D ). Thus, inhibition of mTORC1 pathway by rapamycin only partially reduced the cardiac hypertrophy of R2M hearts.
FoxO Pathway Was Inactivated in R2M Hearts
In searching for additional mechanisms responsible for the abnormal cardiac growth, we found that another downstream target of Akt, FoxO, was highly phosphorylated and inactivated in R2M hearts ( Figure 4A ). In R2M hearts, increased phosphorylation of FoxO3a at multiple Akt target sites was observed, and this was associated with decreased nuclear localization of FoxO3a protein and a lower level of total FoxO3a protein ( Figure 4B ), suggesting that increased phosphorylation of FoxO3a promoted its export from the nucleus and subsequent degradation in the cytosol. Increased phosphorylation of FoxO1a at Akt target sites was also observed, but there was no change in total FoxO1a protein. Inactivation of FoxO was further indicated by changes in the expression of its downstream targets, MURF1 and cyclin D1 ( Figure  4A ). Upregulation of cyclin D1 resulted in a higher protein level in both the nuclear and cytosolic fractions ( Figure 4C ). To restore FoxO activity, we crossed the R2M mice with transgenic mice overexpressing FoxO1a in the heart (FO) because FoxO3a overexpression mice are not viable and FoxO1a has been shown to inhibit cardiac hypertrophy by similar mechanisms as FoxO3a. 19 Overexpression of FoxO1a in R2M hearts (DM-FO) significantly reduced the HW ( Figure  4D ) and the cardiomyocyte cross-sectional area (236±28 μm 2 versus 328±55 μm 2 ; P<0.01; Online Figure VIII) . At the molecular level, the overexpression of FoxO1a decreased phosphorylation of FoxO3a and normalized total Fox3a protein in R2M hearts. The overexpression restored to normal mRNA level of cyclin D1 and MURF1 in DM-FO hearts ( Figure 4E and Online Figure IX) . The overexpression dramatically downregulated cyclin D1 in R2M hearts, whereas it did not affect phosphorylation levels of Akt and S6 ( Figure 4E ). When administrated rapamycin, the DM-FO mice showed a fully normalized heart size compared with NTG (Online Figure VIII) . These data indicate that changes in mTOR-and FoxO-signaling pathway are sufficient to account for the excessive cardiac growth in R2M.
Cardiomyocyte Proliferation Was Increased in R2M Hearts During Postnatal Cardiac Growth
Because the upregulation of cyclin D1 suggests a potential increase of cell proliferation in R2M, we determined whether cellular hyperplasia contributes to the abnormal cardiac growth in R2M mice. Measurements of HW at multiple ages showed that increases in HW to body weight ratios started between 1 and 2 weeks, progressed through the postnatal period, and leveled off after weaning ( Figure 5A ). At 2 weeks when HW to body weight ratios increased by 50% in R2M, cardiomyocyte size did not change in terms of the length and width ( Figure  5B) . Rather, protein level of proliferating cell nuclear antigen, a cell proliferation marker, was elevated during the first 3 weeks after birth in R2M hearts, whereas its level declined sharply in NTG hearts after 1 week ( Figure 5C ). In 2-week-old R2M, mRNA levels were increased for cyclin D1 (1.7-fold), D2 (1.7-fold), and E (2.3-fold) and so were protein levels of cyclin D1 (4.1-fold) and D2 (1.7-fold; Figure 5D and 5E). We subsequently performed immunohistological analysis of 2-week-old hearts using antibodies against proliferation markers, Ki67 and phospho-histone 3 (PH3). R2M hearts contained more Ki67+ or PH3+ cells, suggesting an increased cell proliferation ( Figure 6A ). The total number of cells (based on 4',6-diamidino-2-phenylindole staining) or cardiomyocytes (based on GATA binding protein 4 staining) per cross section of the heart was also increased in R2M ( Figure 6B ). There was no difference in the distribution of mono-versus multi-nucleated cardiomyocytes between the 2 groups (Online Figure X) . BrdU labeling between 1 and 2 weeks after birth demonstrated that there was a modest increase in the percentage of all cell types that incorporated BrdU in R2M hearts compared with age-matched NTG (25% versus 30%). However, the fraction of cardiomyocytes in R2M hearts that incorporated BrdU was increased by 2-fold, indicating that a higher rate of cardiomyocyte proliferation during this period ( Figure 6C ). Comparing hearts at 2 weeks with that at 2 months, we found that the number of PH3 + cells decreased substantially in the adult hearts in both genotypes ( Figure 7A-7C ). However, at either age, the number of proliferating cells was 3-to 5-fold higher in R2M hearts compared with age-matched NTG. Importantly, the PH3 + cardiomyocyte was absent in NTG hearts but present albeit at a much lower frequency in adult R2M hearts. Overexpression of FoxO1a in R2M eliminated the proliferating cardiac myocytes in the adult heart ( Figure 7C ). Taken together, these findings show that increased heart size in R2M resulted from increases of both cell number and cell size, demonstrating that the mutation of γ2-AMPK stimulates cardiac growth by promoting cardiomyocyte proliferation and enhancing hypertrophic growth.
Discussion
This study demonstrates that point mutation of Prkag2 causes glycogen storage and cardiac hypertrophy via distinct mechanisms. By abrogating G6P-stimulated activity of GYS1, we have rescued pathological glycogen storage and consequently the preexcitation phenotype in the mouse model of Prkag2 cardiomyopathy. However, the effects of Prkag2 mutation on cardiac growth are independent of glycogen storage or preexcitation and cannot be rescued by reducing glycogen content of the heart. The mutation, via enhanced insulin sensitivity and activation of Akt, stimulates cardiomyocyte proliferation during postnatal growth by downregulating FoxO signaling and promoting cardiac hypertrophy via mTOR activation in the developed hearts. These findings elucidate important mechanisms underlying Prkag2 cardiomyopathy, and furthermore, reveal a novel function of γ2-AMPK that is critical for the use of AMPK as a therapeutic target.
Although the most common clinical complaint of Prkag2 cardiomyopathy is preexcitation arrhythmia, the unique characteristics of the disease, ventricular preexcitation associated with severe cardiac hypertrophy and glycogen storage, distinguish it from Wolff-Parkinson-White syndrome with structurally normal hearts. 5, 6, 20, 21 Rather, the cardiomyopathy phenotype seems to be similar to glycogen storage diseases caused by mutation in lysosomal associated membrane protein 2 and α-galactosidase A. 20, [22] [23] [24] Different from most forms of glycogen storage disease, mouse hearts expressing mutant Prkag2 are able to use glycogen while faithfully recapitulating the human cardiomyopathy phenotypes, suggesting that the disease mechanism is attributable to an imbalance of glycogen synthesis and use. 8, 11 Elimination of excessive glycogen accumulation by targeting the G6Pstimulated activity of GYS1, shown here, corroborates the prior metabolic flux analysis and provides definitive evidence that enhanced glycogen synthesis because of high intracellular glucose, and G6P is responsible for the glycogen storage in Prkag2 cardiomyopathy. 10 Furthermore, it provides an opportunity to distinguish the direct consequence of Prkag2 mutation from changes secondary to glycogen storage. The rescue of preexcitation in the double mutant heart shows that the arrhythmia is a consequence of glycogen storage rather than a direct effect of AMPK on ion channels as previously speculated. [25] [26] [27] It is also noteworthy that the reduction of glycogen storage is associated with improvement of cardiac function, suggesting that strategies of preventing/reducing glycogen storage are of therapeutic value. The mechanisms by which glycogen causes cardiac dysfunction remain unclear. We speculate the possible mechanisms for that. First of all, preexcitation can induce cardiac dysfunction. The accessory pathway causing preexcitation has been implicated as the cause of cardiac dysfunction. Many reports have shown that normalization of preexcitation with depletion of the accessory pathway can restore cardiac function. 28, 29 Second, extraordinary glycogen accumulation displaces contractile elements, distorts the overall cell morphology, and causes cardiac dysfunction. 30, 31 Third, when accumulated glycogen is used and metabolized, glycogen metabolism increases lactate production, lowers pH, and hampers contractile ability because of its action on sarcomeric protein. The improved cardiac function by lowering glycogen content may result from any one of the above-mentioned mechanisms.
Surprisingly, cardiac hypertrophy remains even after glycogen storage is prevented and ventricular preexcitation rescued in the double mutant heart, indicating that the abnormal cardiac growth was regulated by separate mechanisms. Previous studies have shown that the Prkag2 cardiomyopathy is dependent on the kinase activity of AMPK, 8 but the cardiac hypertrophy phenotype is contrary to the classic paradigm of AMPK function in cell growth, thus presenting a puzzle for the field. Several studies have shown that AMPK inhibits protein synthesis and cell growth under stress conditions by inhibiting mTOR signaling via phosphorylation of TSC2 and raptor. 16, 17 Consistent with this notion, activation of AMPK by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside in cultured neonatal cardiac myocytes prevents agonist-induced hypertrophy. 32 In the Prkag2 mutant heart, however, increased phosphorylation of TSC2 and raptor is observed both at the AMPK and the Akt sites reflecting increases both in AMPK activity and insulin sensitivity of these hearts. This is unique to the Prkag2 mutant heart in which the activation of AMPK occurs under nutrient rich and energy sufficient conditions 10, 11 in contrast to stress-induced activation of AMPK, which is invariantly associated with energy deficit. The resultant activation of the mTOR pathway suggests that the insulin-stimulated phosphorylation cascade overrides the inhibitory regulation of AMPK on mTOR activity, leading to a progrowth phenotype in the mutant heart. Similarly, increased Akt activity and p70S6K phosphorylation have been reported in another mouse model harboring T400N point mutation of Prkag2 with increases of AMPK activity in the heart. 33 It has recently been shown that γ2-subunit is abundantly expressed in the fetal heart; its expression falls sharply after birth but reappears in cardiac hypertrophy and failure. 34, 35 Our results show that activation of γ2-containing AMPK in the postnatal period results in failure to arrest cardiomyocyte proliferation A C B Figure 6 . Cell proliferation was increased in the hearts of R2M mice during postnatal growth. A, Left, Representative confocal image of 2-week-old NTG and R2M hearts stained for phosphorylated-histone 3 (PH3, red, top), Ki67 (green, bottom), 4',6-diamidino-2-phenylindole (DAPI; blue), and merged image (merge). Right, Quantification of cells stained positive for PH3 or Ki67 in 1 cross section of the hearts from 2-week-old mice (n=6 for each genotype; scale bar, 50 μm). B, Top, Representative confocal image of a 2-week-old R2M heart stained for α-sarcomeric actin (α-SA, red), GATA binding protein 4 (GATA4) (green), DAPI (blue), and merged image (merge). Bottom, Quantification of all nuclei (DAPI + ) and cardiomyocyte nuclei (GATA4 + α-SA + ) in each cross section of the hearts (n=4 for each gentoype; scale bar, 10 μm). C, Top, 5-bromo-2-deoxyuridine (BrdU) was injected into 1-week-old pups for 7 days. Hearts were harvested at 2 weeks. Heart sections were stained for GATA4 (green), BrdU (red), and DAPI (blue). Arrow indicate cardiomyocyte with BrdU incorporation. Bottom, Percentage of proliferative cells (BrdU + /DAPI + ) and percentage of proliferative cardiomyocyte (GATA4 + BrdU + / GATA4 + ) in the 2-week-old heart. Thirty random fields were counted in each section (n=3; scale bar, 10 μm; *P<0.05 vs NTG). during maturation, hence revealing a novel function of γ2-AMPK in cell cycle progression of post mitotic myocytes. In nonmyocytes, activated AMPK complex has been shown to localize in the mitotic apparatus in human cancer cells, 36 and AMPK phosphorylates proteins involved in cell cycle and promotes cell cycle progression in human endothelial cells. 37 Loss of AMPK function delays cell cycle progression in Drosophila, as well as in mammalian cells. [38] [39] [40] It remains to be determined whether the function of AMPK in the proliferation of those cell types is dependent on the isoform composition, the energy status, or both. Because the human phenotype of Prkag2 mutations is restricted to the heart in spite of the ubiquitous expression in adult tissues, it is possible that unique functions of γ2-subunit or expressions of unique splice variant(s) of the protein exist in the heart as previously suggested. 35 In summary, we show that mutation of the γ2-subunit of AMPK accentuates insulin signaling, increases cell proliferation during the postnatal growth period, and stimulates myocyte hypertrophy in adulthood, leading to abnormal cardiac growth in Prkag2 cardiomyopathy. These changes are attributable to mechanisms independent of glycogen accumulation in the heart, thus providing new insights to the pathogenesis of Prkag2 cardiomyopathy. The findings also underscore the importance of isoform-specific function of AMPK that is critical for the pharmacological targeting of the AMPK. 
